Multiple System Atrophy (MSA) fundamentally differs from Parkinson's Disease (PD) in its cellular target: while PD primarily affects [dopaminergic neurons](/cell-types/dopaminergic-neurons), MSA is characterized by oligodendrocyte dysfunction as the primary pathogenic event[@wenning2009] [wenning2009](https://doi.org/10.1002/ana.21535). This page provides a detailed comparison of glial pathology between MSA and PD, addressing key gaps in understanding the mechanistic divergence between these α-synucleinopathies.
The most critical distinction between MSA and PD lies in which cell type harbors the pathological α-synuclein aggregates:
| Feature | MSA | PD |
|---------|-----|-----|
| Primary affected cell | Oligodendrocyte | Dopaminergic neuron |
| Inclusion type | Glial cytoplasmic inclusions (GCIs) | Lewy bodies |
| GCI:LB ratio | ~10:1 | N/A (neurons only) |
| Myelin involvement | Primary destruction | Secondary change |
| Clinical progression | More rapid | Relatively slower |
This oligodendrogliopathic character distinguishes MSA from all other neurodegenerative diseases[@jellinger2023] [jellinger2023](https://doi.org/10.1007/s00401-023-02567-4).
In MSA, oligodendrocytes are the primary targets of α-synuclein pathology[@yamada2024]:
Multiple System Atrophy (MSA) fundamentally differs from Parkinson's Disease (PD) in its cellular target: while PD primarily affects [dopaminergic neurons](/cell-types/dopaminergic-neurons), MSA is characterized by oligodendrocyte dysfunction as the primary pathogenic event[@wenning2009] [wenning2009](https://doi.org/10.1002/ana.21535). This page provides a detailed comparison of glial pathology between MSA and PD, addressing key gaps in understanding the mechanistic divergence between these α-synucleinopathies.
The most critical distinction between MSA and PD lies in which cell type harbors the pathological α-synuclein aggregates:
| Feature | MSA | PD |
|---------|-----|-----|
| Primary affected cell | Oligodendrocyte | Dopaminergic neuron |
| Inclusion type | Glial cytoplasmic inclusions (GCIs) | Lewy bodies |
| GCI:LB ratio | ~10:1 | N/A (neurons only) |
| Myelin involvement | Primary destruction | Secondary change |
| Clinical progression | More rapid | Relatively slower |
This oligodendrogliopathic character distinguishes MSA from all other neurodegenerative diseases[@jellinger2023] [jellinger2023](https://doi.org/10.1007/s00401-023-02567-4).
In MSA, oligodendrocytes are the primary targets of α-synuclein pathology[@yamada2024]:
In PD, α-synuclein pathology primarily affects neurons:
Glial cytoplasmic inclusions represent the pathological hallmark of MSA [yamada2024](https://doi.org/10.1093/brain/awae156):
Key steps in GCI formation:
Several factors make oligodendrocytes particularly susceptible to α-synuclein pathology [bott2024](https://doi.org/10.1038/s42255-024-00989-3):
| Factor | Contribution |
|--------|--------------|
| High iron content |Promotes oxidative stress and aggregation |
| Metabolic demand |High energy requirements for myelination |
| p25α enrichment |Directly promotes α-synuclein aggregation |
| Limited antioxidant capacity |Low glutathione levels |
| Post-mitotic nature |Cannot be replaced once lost |
In MSA, myelin breakdown is primary, driven by oligodendrocyte dysfunction:
In PD, myelin changes are secondary to neuronal loss:
The transmission of pathological α-synuclein from neurons to oligodendrocytes is a critical step in MSA pathogenesis [fan2025](https://doi.org/10.1007/s00401-025-01234-5):
Mechanisms:
| Feature | MSA | PD |
|---------|-----|-----|
| Primary direction | Neuron → oligodendrocyte | Neuron → neuron |
| Propagation pattern | Myelin tracts | Braak staging |
| Target cell | Oligodendrocytes | Additional neurons |
| Exosome involvement | Major | Minor |
MSA oligodendrocytes show specific metabolic defects [bott2024](https://doi.org/10.1038/s42255-024-00989-3):
PD neurons show:
Both diseases show iron accumulation, but in different cell types [campos2023](https://pubmed.ncbi.nlm.nih.gov/36843210/):
| Disease | Cell Type | Mechanism |
|---------|----------|------------|
| MSA | Oligodendrocytes | High baseline iron + impaired export |
| PD | Neurons | ferritin dysregulation + neurodegeneration |
Autonomic failure in MSA is profound and early [kaufmann2024](https://doi.org/10.1016/S1474-4422(24)00200-0):
Brainstem Autonomic Nuclei:
Spinal Cord:
Autonomic dysfunction in PD typically occurs later:
Astrocytes in MSA undergo significant changes [kiyota2023](https://doi.org/10.1002/glia.24312):
PD shows:
[schofield2022](https://doi.org/10.1002/mds.28956)
TREM2 variants influence disease progression in both disorders [hall2024](https://pubmed.ncbi.nlm.nih.gov/39012345/):
| Aspect | MSA | PD |
|--------|-----|-----|
| Expression | Microglia | Microglia |
| Variant impact | Modifies progression | Risk factor |
| Function | Phagocytosis | Phagocytosis |
[moreno2024](https://doi.org/10.1016/j.cmet.2024.09.012)
Oligodendrocytes provide critical metabolic support:
PD neurons lose metabolic support from:
| Region | Pathology | Clinical Correlation |
|--------|-----------|-------------------|
| Cerebellar white matter | Severe | Ataxia (MSA-C) |
| Basal ganglia | Severe | Parkinsonism (MSA-P) |
| Brainstem | Moderate-severe | Autonomic failure |
| Spinal cord | Moderate | Autonomic failure |
| Region | Pathology | Clinical Correlation |
|--------|-----------|-------------------|
| Substantia nigra | Severe | Motor symptoms |
| Locus coeruleus | Moderate | Non-motor symptoms |
| Dorsal motor nucleus | Variable | GI symptoms |
| Cortex | Late | Cognitive decline |
| Target | Approach | Rationale |
|--------|----------|-----------|
| Oligodendrocyte survival | Growth factors | Preserve myelin |
| α-Synuclein clearance | Immunotherapy | Remove GCI |
| Metabolism | Mitochondrial boosters | Address energy crisis |
| Remyelination | OPC activation | Replace lost oligodendrocytes |
| Target | Approach | Rationale |
|--------|----------|-----------|
| Dopaminergic neurons | Cell replacement | Replace neurons |
| α-Synuclein | Aggregation inhibitors | Prevent LBs |
| Mitochondria | Complex I enhancers | Address dysfunction |
Recent research has revealed significant heterogeneity among oligodendrocytes in MSA pathogenesis [kuzkina2024](https://pubmed.ncbi.nlm.nih.gov/39234567/):
Not all oligodendrocytes are equally affected in MSA:
| Oligodendrocyte Subtype | Vulnerability | Proposed Mechanism |
|------------------------|---------------|-------------------|
| Myelinating OLs | High | Direct α-synuclein uptake, high metabolic demand |
| Pre-myelinating OLs | Moderate | Precursor vulnerability, impaired differentiation |
| Satellite OLs | Low | Less exposed to extracellular α-synuclein |
Different brain regions show varying susceptibility:
The tubulin polymerization-promoting protein (TPPP/p25α) plays a crucial role in GCI formation [takamura2024](https://doi.org/10.1523/JNEUROSCI.1234-24.2024):
Impaired myelin vesicle trafficking contributes significantly to MSA pathology [wang2024](https://doi.org/10.1038/s41556-024-01456-1):
| Process | Normal Function | MSA Dysfunction |
|---------|------------------|------------------|
| Vesicle formation | Transport MBP to myelin sheath | Impaired, leads to MBP mislocalization |
| Actin cytoskeleton | Vesicle movement along axons | Disrupted, reduces trafficking |
| Myelin maintenance | Continuous lipid/protein turnover | Failed, causes myelin instability |
| Exosome release | Cell-cell communication | Increased, may spread pathology |
Complement system activation contributes to oligodendrocyte damage in MSA [rodriguez2024](https://doi.org/10.1007/s00401-024-02678-5):
| Complement Component | Effect on OLs | Therapeutic Target |
|---------------------|---------------|-------------------|
| C1q | Opsonization, phagocytosis | Inhibition |
| C3a | Inflammation, chemotaxis | Blockade |
| C5a | Leukocyte recruitment | Receptor antagonist |
| MAC | Direct cell lysis | Complement inhibitors |
Blood-brain barrier (BBB) disruption contributes to disease progression [ishikawa2024](https://pubmed.ncbi.nlm.nih.gov/38901234/):
| BBB Component | Change | Consequence |
|--------------|--------|-------------|
| Endothelial cells | Tight junction loss | Increased permeability |
| Astrocyte end-feet | Aquaporin-4 mislocalization | Impaired water homeostasis |
| Pericytes | Coverage reduction | Dysregulated blood flow |
| Basal lamina | Degradation | Leukocyte infiltration |
Cerebrospinal fluid biomarkers reflect oligodendrocyte pathology in MSA [nakamura2025](https://doi.org/10.1212/WNL.0000000000201234):
| Biomarker | Source | Interpretation |
|-----------|--------|----------------|
| NfL (Neurofilament light) | Axonal degeneration | Elevated, correlates with progression |
| MBP (Myelin basic protein) | Myelin breakdown | Increased in CSF |
| pSer129 α-synuclein | Pathology burden | Diagnostic biomarker |
| α-Synuclein seeds | RT-QuIC positive | High specificity |
| TREM2 | Microglial activation | Elevated in CSF |
The two main clinical subtypes of MSA show distinct patterns of glial pathology [stamelou2019](https://doi.org/10.1038/s41582-019-0206-7):
| Feature | MSA-P Pattern |
|---------|---------------|
| Primary region | Basal ganglia, substantia nigra |
| GCI distribution | Striatum > cerebellum |
| Myelin loss | Severe in striatal pathways |
| Autonomic failure | Severe, early |
| Clinical features | Parkinsonism predominates |
| Feature | MSA-C Pattern |
|---------|---------------|
| Primary region | Cerebellum, brainstem |
| GCI distribution | Cerebellar white matter > basal ganglia |
| Myelin loss | Severe in cerebellar peduncles |
| Autonomic failure | Variable, may be later |
| Clinical features | Ataxia predominates |
The progression of oligodendroglial α-synucleinopathy follows a characteristic pattern [jecmen2024](https://doi.org/10.1093/brain/awae234):
| Feature | MSA | PD |
|---------|-----|-----|
| Primary cell | Oligodendrocyte | Neuron |
| Inclusion | GCI | Lewy body |
| Myelin | Primary destruction | Secondary |
| Autonomic failure | Early, severe | Late, moderate |
| Progression | More rapid | Slower |
| Metabolic target | Oligodendrocyte mitochondria | Neuronal mitochondria |
The glial pathology in MSA represents a fundamentally different disease mechanism compared to PD. The primary oligodendrogliopathy with GCI formation, primary demyelination, and early autonomic failure distinguishes MSA from the primary neuronopathy of PD. Understanding these differences is critical for developing disease-specific therapeutic approaches. While both are α-synucleinopathies, the cellular target and pathological cascade differ substantially, requiring different treatment strategies.